Chapter 1
NEW MICROBIAL DEMANDS AND MAJOR DRIVERS OF THE ANTI-INFECTIVE MARKETPLACE
1.1. The Emergence, Re-emergence, and Spread of Infectious Diseases
1.2. The Very Serious Problem of Drug Resistance
1.3. Biodefense
1.4. Technological Growth and Increased Knowledge
1.5. Growing Concerns about Food Safety
1.6. Animal Health
1.7. The Infectious Etiology of Chronic Diseases

Chapter 2
THERAPEUTIC CHILLENGES: MICROBES AS MOVING TARGETS
2.1. Introduction
2.2. HIV/AIDS Antiretrovirals: Growth in a Mature Market
2.3. Adding to the Antibiotic Arsenal
Phage Therapy: A New Market Niche for Alternative Antibacterials?
2.4. Bird Flu
The Current Avian Influenza A (H5N1) Outbreak
Influenza Therapeutics
Oseltamivir (Tamiflu)
2.5. Retroviruses: A Global Threat More Serious Than Influenza?
2.6. Vaccine Industry Challenges
Infectious Agent Vaccines for the Prevention of Chronic Disease
Human Papilloma Virus Vaccines
Changing Trends in Vaccine Technology and Targets
New Vaccine Targets
The Race To Make a Universal Influenza Vaccine
M2 Vaccines
NP Vaccines
When Will Plant-Based Vaccines Be Ripe for Marketing?
 
Chapter 3
DOING THE DETECTIVE WORK: INFECTIOUS DISEASE DIAGNOSTICS
3.1. Introduction
3.2. Molecular Diagnostics
Advantages of Molecular Versus Culture-Based Detection
Human Papilloma Virus Testing: The Fastest-Growing Molecular Diagnostic Test
HIV and HCV Viral Load Tests
HCV Testing
3.3. Blood Safety: The Emerging Problem of Bacterial Contamination
Other Blood-Borne Pathogens of Concern
The Emerging Problem of Transfusion-Associated Bacterial Contamination
3.4. The 2003 to 2006 Avian Influenza Outbreak: The Importance of Rapid Diagnostic Testing
Prompt Treatment
Surveillance and WHO Notification
Preventing Dissemination and Opportunities for Viral Evolution
The Ideal Influenza Test
Available Avian Influenza Diagnostic Tests
PCR-Based Nucleic Acid Amplification Tests
Commercial Availability of “Rapid” Tests Still Requiring Validation
 
Chapter 4
COMMERCIAL OPPORTUNITIES: COMFORTABLE NICHES EXIST FOR BOTH BIG PHARMA AND SMALL BIOTECHS
4.1. Introduction
4.2. Patent Expiration and Price Drops
4.3. Antimicrobial Resistance and Market Opportunities
Products and Profitability: Major and Small-Company Players
4.4. Biodefense: A Call to Industry
Opportunities and Challenges for Small Companies Seeking Government Biodefense Contracts
Companies on Government Contract
Finding the Funds
Efforts to Strengthen BioShield: Looking to Large Pharma
4.5. The Present and Future Burden of Infectious Disease
4.6. Finding Your Market Niche
4.7. Neglected Infectious Disease Drug Development: Opportunities for All, Big and Small
Major Neglected Infectious Diseases
Malaria
Tuberculosis
Onchocerciasis
Dengue
Visceral Leishmaniasis
Lymphatic Filariasis
4.8. Collaboration and Consolidation
4.9. The Biggest Challenge Is Basic Science: The Red Queen Race
 
Chapter 5
COMPANY PROFILES
5.1. Acambis
5.2. Adlyfe Inc.
5.3. Akonni Biosystems
5.4. Alnylam Pharmaceuticals
5.5. Arbor Vita Corporation
5.6. Biophage Pharma Inc.
5.7. CEL-SCI Corporation
5.8. CombiMatrix Corporation
5.9. Cubist Pharmaceuticals, Inc.
5.10. Gilead Sciences, Inc.
5.11. NanoBio Corporation
5.12. Nanosphere, Inc.
5.13. Obetech, LLC
5.14. Panacos Pharmaceuticals, Inc.
5.15. PowderMed Limited
5.16. Progenics Pharmaceuticals, Inc.
5.17. Ribomed Biotechnologies, Inc.
5.18. Tanox, Inc.
5.19. Targanta Therapeutics, Inc.
5.20. Tm Bioscience Corporation

APPENDIX
CHI ADVANCES INFECTIOUS DISEASE SURVEY – July/August 2006 (n = 83)

References

Glossary

Company Index with Web Sites